[{"id":"2f06742a-ebd4-48e5-afcc-2ee4cb157495","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135261","created_at":"2021-06-21T23:52:30.283Z","updated_at":"2024-07-02T16:35:50.342Z","phase":"Phase 1","brief_title":"A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of a Study Drug in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT04135261","lead_sponsor":"Harbour BioMed US, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e porustobart (HBM4003)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 01/17/2023","primary_completion_date":" 01/17/2023","study_txt":" Completion: 02/15/2023","study_completion_date":" 02/15/2023","last_update_posted":"2023-04-18"},{"id":"37c93dcf-0093-43c3-830a-08c64e0071f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04866485","created_at":"2021-04-29T11:55:49.966Z","updated_at":"2024-07-02T16:36:30.964Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody","source_id_and_acronym":"NCT04866485","lead_sponsor":"Harbour BioMed (Guangzhou) Co. Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • porustobart (HBM4003)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/14/2021","start_date":" 06/14/2021","primary_txt":" Primary completion: 02/01/2023","primary_completion_date":" 02/01/2023","study_txt":" Completion: 02/01/2023","study_completion_date":" 02/01/2023","last_update_posted":"2021-04-29"}]